Abstract：
UNASSIGNED: CAR T cells have generated great excitement due to their remarkable clinical response rates in selected hematologic malignancies. However, these engineered immune cells are living drugs which are hard to control after administration.
UNASSIGNED: We discuss small molecule-regulated switch systems which can potentially be used to control CAR T cell function within the patient, as well as the most important obstacles in the CAR T cell field, which might be overcome with those switch systems.
UNASSIGNED: There is an urgent need to develop advanced switch systems. Once available, we expect that they will open up new avenues for future CAR T cell generations.
UNASSIGNED: We discuss small molecule-regulated switch systems which can potentially be used to control CAR T cell function within the patient, as well as the most important obstacles in the CAR T cell field, which might be overcome with those switch systems.
UNASSIGNED: There is an urgent need to develop advanced switch systems. Once available, we expect that they will open up new avenues for future CAR T cell generations.
摘要：
■CART细胞由于其在选定的血液恶性肿瘤中的显着临床反应率而产生了极大的兴奋。然而,这些工程免疫细胞是活的药物，给药后难以控制。
■我们讨论了小分子调节的开关系统，该系统可能用于控制患者体内的CAR-T细胞功能，以及CAR-T细胞领域最重要的障碍，这些开关系统可能会克服。
■迫切需要开发先进的交换机系统。一旦可用，我们预计它们将为未来的CAR-T细胞世代开辟新的途径。
■我们讨论了小分子调节的开关系统，该系统可能用于控制患者体内的CAR-T细胞功能，以及CAR-T细胞领域最重要的障碍，这些开关系统可能会克服。
■迫切需要开发先进的交换机系统。一旦可用，我们预计它们将为未来的CAR-T细胞世代开辟新的途径。
